Dominican Republic Patients Wait Over 5 Years for Access to Innovative Medications

A new study reveals that patients in the Dominican Republic face an average wait time of nearly six years to access innovative medications, a critical healthcare access challenge mirrored across Latin America. The WAIT 2026 index, developed by IQVIA and FIFARMA with participation from local organizations including the Central American Federation, documents significant delays in drug availability that impact treatment outcomes for patients with serious conditions. These extended wait times underscore systemic barriers in regulatory approval processes and pharmaceutical distribution networks throughout the region. For Puerto Rico residents with family ties to the Dominican Republic or those considering regional healthcare options, understanding these disparities is essential for informed medical decision-making. Addressing these delays requires coordinated efforts among regulatory bodies, pharmaceutical companies, and healthcare policymakers to expedite patient access to life-saving treatments.